Apollomics Inc Cl A (APLM)

$19.54 -2.23 (-10.24%)
Market Cap 20.19M
Revenue (ttm) 1.49M
Net Income (ttm) -53.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,614.77%
Debt to Equity Ratio 0.00
Volume 5,200
Avg Vol 25,624
Day's Range N/A - N/A
Shares Out 1.10M
Stochastic %K 49%
Beta 1.79
Analysts Strong Buy
Price Target $6.50

Company Profile

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; APL-102, an oral active, small molecule multip...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 209 4055
Fax: 650 288 1674
Address:
989 East Hillsdale Blvd., Suite 220, Foster City, United States
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 25 at 3:38 AM
$APLM RSI: 43.64, MACD: 0.3708 Vol: 1.25, MA20: 20.07, MA50: 18.06 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BSMARKET
BSMARKET Jan. 14 at 3:03 PM
$APLM $THH $ANPA
0 · Reply
BSMARKET
BSMARKET Jan. 13 at 11:52 PM
$APLM will follow $THH $ANPA same territory
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 31 at 4:13 PM
$APLM
0 · Reply
caprihunter
caprihunter Dec. 29 at 3:44 PM
$MMA $HIT.X $CABR $APLM $PRAX
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 26 at 7:27 PM
$APLM RSI: 59.40, MACD: 0.2437 Vol: 1.53, MA20: 16.28, MA50: 18.20 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
RiskPoolingR
RiskPoolingR Dec. 25 at 7:59 AM
$APLM Market tolerance narrows as uncertainty lingers, while management calibrates resource allocation to real demand signals. Clear follow‑through could unlock sustainable re‑rating.
0 · Reply
Tstockwizard
Tstockwizard Dec. 16 at 8:36 PM
$APLM
0 · Reply
DARKP00L
DARKP00L Dec. 12 at 5:00 PM
$APLM 11:43 on Dec. 12 2025 On December 11, 2025 Apollomics Issued Formal Notice Of Termination To Edison Oncology Related To Development And Commercialization Of APL-122; Terminating Agreement On Basis That Edison Failed To Fulfill Certain Material Performance & Reporting Obligations; Co Does Not Expect Termination To Have Material Adverse Effect On Its Overall Financial Condition Or Results Of Operations #tradeideas
0 · Reply
TheRealBearKillaAlerts
TheRealBearKillaAlerts Dec. 11 at 1:48 PM
$APLM bullish move incoming! Chart is hot! 🚀
0 · Reply
Latest News on APLM
Apollomics Reports First Half 2025 Financial Results

Dec 22, 2025, 4:05 PM EST - 6 weeks ago

Apollomics Reports First Half 2025 Financial Results

Apollomics Announces Settlement of Cayman Litigation

Nov 19, 2025, 5:38 PM EST - 2 months ago

Apollomics Announces Settlement of Cayman Litigation

Apollomics Announces Changes to its Board of Directors and Composition of Committees

Nov 17, 2025, 11:00 PM EST - 2 months ago

Apollomics Announces Changes to its Board of Directors and Composition of Committees

Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation

Oct 15, 2025, 2:36 PM EDT - 3 months ago

Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation

Apollomics, Inc. Company Operational Continuity Update

Oct 13, 2025, 9:22 PM EDT - 4 months ago

Apollomics, Inc. Company Operational Continuity Update

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

Apr 3, 2025, 4:05 PM EDT - 10 months ago

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

Mar 31, 2025, 8:00 AM EDT - 11 months ago

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Dec 20, 2024, 8:00 AM EST - 1 year ago

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Dec 10, 2024, 4:05 PM EST - 1 year ago

Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Aug 14, 2024, 6:00 AM EDT - 1 year ago

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Jul 16, 2024, 4:47 PM EDT - 1 year ago

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Apollomics Announces Updated Strategic Focus and Leadership Team Changes

Jul 3, 2024, 8:00 AM EDT - 1 year ago

Apollomics Announces Updated Strategic Focus and Leadership Team Changes

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Apr 25, 2024, 8:30 AM EDT - 1 year ago

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Apr 10, 2024, 7:00 AM EDT - 1 year ago

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Apollomics, Inc. (APLM) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 3:57 PM EDT - 2 years ago

Apollomics, Inc. (APLM) Q4 2023 Earnings Call Transcript

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Mar 28, 2024, 7:00 AM EDT - 2 years ago

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

Mar 4, 2024, 7:00 AM EST - 2 years ago

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 7, 2024, 7:00 AM EST - 2 years ago

Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Jan 19, 2024, 4:15 PM EST - 2 years ago

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apollomics to Participate in a Fireside Chat at the B. Riley Securities' 2024 Virtual Oncology Conference

Jan 17, 2024, 4:30 PM EST - 2 years ago

Apollomics to Participate in a Fireside Chat at the B. Riley Securities' 2024 Virtual Oncology Conference

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Jan 3, 2024, 7:00 AM EST - 2 years ago

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Apollomics to Present at the 2024 Biotech Showcase

Jan 2, 2024, 4:30 PM EST - 2 years ago

Apollomics to Present at the 2024 Biotech Showcase

Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Nov 29, 2023, 7:30 AM EST - 2 years ago

Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)

Nov 28, 2023, 7:00 AM EST - 2 years ago

Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)

Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer

Nov 16, 2023, 8:30 AM EST - 2 years ago

Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer

Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation

Oct 31, 2023, 8:30 AM EDT - 2 years ago

Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation

Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion

Oct 26, 2023, 8:50 AM EDT - 2 years ago

Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion

Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%

Oct 23, 2023, 8:30 AM EDT - 2 years ago

Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%

Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023

Oct 16, 2023, 6:55 PM EDT - 2 years ago

Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023

Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

Sep 28, 2023, 4:17 PM EDT - 2 years ago

Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Apollomics: A Taiwanese-Origin Company With Late Stage Pipeline

Aug 29, 2023, 6:21 AM EDT - 2 years ago

Apollomics: A Taiwanese-Origin Company With Late Stage Pipeline

Top 5 Health Care Stocks That Are Preparing To Pump In Q2 - AngioDynamics (NASDAQ:ANGO), Apollomics (NASDAQ:APLM)

Apr 26, 2023, 7:45 AM EDT - 3 years ago

Top 5 Health Care Stocks That Are Preparing To Pump In Q2 - AngioDynamics (NASDAQ:ANGO), Apollomics (NASDAQ:APLM)

ANGO

Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R.

Apr 11, 2023, 8:30 AM EDT - 3 years ago

Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R.

Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination

Jan 13, 2023, 4:13 PM EST - 3 years ago

Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination

Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination

Oct 7, 2022, 4:05 PM EDT - 3 years ago

Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination

OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 25 at 3:38 AM
$APLM RSI: 43.64, MACD: 0.3708 Vol: 1.25, MA20: 20.07, MA50: 18.06 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BSMARKET
BSMARKET Jan. 14 at 3:03 PM
$APLM $THH $ANPA
0 · Reply
BSMARKET
BSMARKET Jan. 13 at 11:52 PM
$APLM will follow $THH $ANPA same territory
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 31 at 4:13 PM
$APLM
0 · Reply
caprihunter
caprihunter Dec. 29 at 3:44 PM
$MMA $HIT.X $CABR $APLM $PRAX
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 26 at 7:27 PM
$APLM RSI: 59.40, MACD: 0.2437 Vol: 1.53, MA20: 16.28, MA50: 18.20 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
RiskPoolingR
RiskPoolingR Dec. 25 at 7:59 AM
$APLM Market tolerance narrows as uncertainty lingers, while management calibrates resource allocation to real demand signals. Clear follow‑through could unlock sustainable re‑rating.
0 · Reply
Tstockwizard
Tstockwizard Dec. 16 at 8:36 PM
$APLM
0 · Reply
DARKP00L
DARKP00L Dec. 12 at 5:00 PM
$APLM 11:43 on Dec. 12 2025 On December 11, 2025 Apollomics Issued Formal Notice Of Termination To Edison Oncology Related To Development And Commercialization Of APL-122; Terminating Agreement On Basis That Edison Failed To Fulfill Certain Material Performance & Reporting Obligations; Co Does Not Expect Termination To Have Material Adverse Effect On Its Overall Financial Condition Or Results Of Operations #tradeideas
0 · Reply
TheRealBearKillaAlerts
TheRealBearKillaAlerts Dec. 11 at 1:48 PM
$APLM bullish move incoming! Chart is hot! 🚀
0 · Reply
PnLCoreBotX_1373
PnLCoreBotX_1373 Dec. 5 at 8:32 PM
$APLM thin microcap, watch for higher lows and fresh volume
0 · Reply
Godwins26
Godwins26 Nov. 24 at 8:18 PM
2nd Watchlist for today 😊 $NVVE watch closely 👀 right now $IVP $AGRZ $APLM $ABTS
0 · Reply
Hodler9
Hodler9 Nov. 23 at 2:39 PM
$AIXI let’s see if aixi gets that bounce back to 1$ next week 🤞 $APLM $MGRX $SHPH
0 · Reply
stockanalysis_
stockanalysis_ Nov. 21 at 9:26 PM
After Hours Losers: $SHPH $AIIO $APLM $AIXI $MGRX https://stockanalysis.com/markets/afterhours/losers/?ref=saveontrading
0 · Reply
DARKP00L
DARKP00L Nov. 19 at 9:11 PM
$APLM 16:11 on Nov. 19 2025 Apollomics Enters Into Settlement Agreement With TWVC Goldlink Partners Investment And TWVC Panglin Group Investment; To Pay $5M In Cash And $879,757.78 In Associated Legal expenses #tradeideas
0 · Reply
Joby099
Joby099 Nov. 18 at 6:01 PM
$DRCT $ALT $BDRX $APLM
0 · Reply
Joby099
Joby099 Nov. 18 at 12:13 PM
$DRCT $ALT $BDRX $APLM
2 · Reply
Joby099
Joby099 Nov. 18 at 1:56 AM
$DRCT $ALT $BDRX $APLM
0 · Reply
Joby099
Joby099 Nov. 17 at 6:53 PM
$DRCT $ALT $BDRX $APLM
0 · Reply
Joby099
Joby099 Nov. 17 at 12:52 PM
$DRCT $ALT $BDRX $APLM
0 · Reply
Joby099
Joby099 Nov. 17 at 1:01 AM
$DRCT $ALT $BDRX $APLM
0 · Reply